Shin Nippon Biomedical Exceeds Financial Forecasts for 2024
Company Announcements

Shin Nippon Biomedical Exceeds Financial Forecasts for 2024

Shin Nippon Biomedical Laboratories, Ltd. (JP:2395) has released an update.

Shin Nippon Biomedical Laboratories, Ltd. reported better-than-expected financial results for the first half of 2024, driven by strong performance in its domestic nonclinical CRO business and lower-than-expected expenses related to an NDA resubmission. The company’s revenue and profits significantly surpassed forecasts, with interim profit showing a remarkable 55.1% increase over projections.

For further insights into JP:2395 stock, check out TipRanks’ Stock Analysis page.

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App